Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research... see more

TSXV:RKV - Post Discussion

Rakovina Therapeutics Inc > The Power Play by The Market Herald Releases New Interviews
View:
Post by Betteryear2 on Nov 16, 2021 6:26pm

The Power Play by The Market Herald Releases New Interviews

Rakovina (RKV) is partnering with St. Baldrick's Foundation to develop treatments for childhood bone cancer. It was selected to join a three-year C$1,297,000 research program funded by St. Baldrick's Martha's BEST Grant for All. The grant focuses on treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults. Dr. Mads Daugaard, Co-founder, President, and CSO sat down with Dave Jackson to discuss Rakovina's partnership with St. Baldrick's Foundation.

For the full interview with Dr. Mads Daugaard and to learn more about Rakovina's recent partnership, click here.

Be the first to comment on this post
Rakovina Therapeutics Inc